Clinical Trial Update: Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis [Phase 1]

View source ↗

Summary

AbbVie has completed a Phase 1 single rising dose study of BI 655066 in adults with moderate-to-severe psoriasis. The report focuses on trial status rather than…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BI 655066

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 1 | Status: COMPLETED